Safety, Efficacy and Biomarker Outcomes of a Novel, Intra-Articular, Injectable, Wnt Inhibitor (SM04690) in the Treatment of Osteoarthritis of the Knee: Interim, Exploratory Analysis of Results from a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study

被引：0
|
作者：
Yazici, Yusuf [1 ]
McAlindon, Timothy E. [2 ]
Fleischmann, Roy [3 ]
Gibofsky, Allan [4 ,5 ]
Lane, Nancy E. [6 ]
Kivitz, Alan J. [7 ]
Skrepnik, Nebojsa [8 ]
Armas, Eddie [9 ]
Swearingen, Christopher J. [1 ]
DiFrancesco, Anita [1 ]
Tambiah, Jeyanesh R. S. [1 ]
Hood, John [1 ]
Hochberg, Marc C. [10 ]
机构：
[1] Samumed, San Diego, CA USA
[2] Tufts Med Ctr, Boston, MA USA
[3] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA
[4] Weill Cornell Med Coll, New York, NY USA
[5] Hosp Special Surg, New York, NY 10021 USA
[6] UC Davis Med Ctr, Sacramento, CA USA
[7] Altoona Ctr Clin Res, Duncansville, PA USA
[8] Tucson Orthopaed Inst, Tucson, AZ USA
[9] Well Pharma Med Res, Miami, FL USA
[10] Univ Maryland, Sch Med, Baltimore, MD 21201 USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2015年 / 67卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
312
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Safety, tolerability and efficacy of intra-articular Progenza in knee osteoarthritis: a randomized double-blind placebo-controlled single ascending dose study
    Kuah, D.
    Sivell, S.
    Longworth, T.
    James, K.
    Guermazi, A.
    Cicuttini, F.
    Wang, Y.
    Craig, S.
    Comin, G.
    Robinson, D.
    Wilson, J.
    JOURNAL OF TRANSLATIONAL MEDICINE, 2018, 16
  • [22] Safety, tolerability and efficacy of intra-articular Progenza in knee osteoarthritis: a randomized double-blind placebo-controlled single ascending dose study
    D. Kuah
    S. Sivell
    T. Longworth
    K. James
    A. Guermazi
    F. Cicuttini
    Y. Wang
    S. Craig
    G. Comin
    D. Robinson
    J. Wilson
    Journal of Translational Medicine, 16
  • [23] Reducing Heterogeneity in OA Clinical Trials: Data from a Phase 2 Study of SM04690, a Novel, Intra-Articular, Wnt Pathway Inhibitor in Knee Osteoarthritis
    Conaghan, Philip G.
    DiFrancesco, Anita
    Swearingen, Christopher J.
    Kennedy, Sarah
    Simsek, Ismail
    Tambiah, Jeymi
    Yazici, Yusuf
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [24] A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study
    Yazici, Y.
    McAlindon, T. E.
    Fleischmann, R.
    Gibofsky, A.
    Lane, N. E.
    Kivitz, A. J.
    Skrepnik, N.
    Armas, E.
    Swearingen, C. J.
    DiFrancesco, A.
    Tambiah, J. R. S.
    Hood, J.
    Hochberg, M. C.
    OSTEOARTHRITIS AND CARTILAGE, 2017, 25 (10) : 1598 - 1606
  • [25] RESULTS FROM A SINGLE CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF INTRA-ARTICULAR ONABOTULINUMTOXINA FOR OSTEOARTHRITIS KNEE PAIN
    Kalunian, K. C.
    Arendt-Nielsen, L.
    Turkel, C. C.
    DeGryse, R.
    McAlindon, T. E.
    Boon, A. J.
    Jiang, G. -L.
    OSTEOARTHRITIS AND CARTILAGE, 2014, 22 : S192 - S192
  • [26] EFFECTS OF INTRA-ARTICULAR CLODRONATE IN THE TREATMENT OF KNEE OSTEOARTHRITIS: RESULTS OF A DOUBLE-BLIND, RANDOMISED PLACEBO-CONTROLLED TRIAL
    Orsolini, G.
    Idolazzi, L.
    Rossini, M.
    Viapiana, O.
    Fracassi, E.
    Povino, M.
    Risoli, M.
    Gatti, D.
    Adami, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 745 - 745
  • [27] PROSPECTIVE COMPARISON OF INTRA-ARTICULAR SHAM VS. PLACEBO INJECTIONS: DATA FROM A RANDOMIZED, CONTROLLED PHASE 2B TRIAL OF SM04690, A WNT PATHWAY INHIBITOR FOR KNEE OSTEOARTHRITIS
    Yazici, Y.
    Tambiah, J.
    Swearingen, C.
    Kennedy, S.
    Strand, V.
    Cole, B.
    Hochberg, M.
    Bannuru, R.
    McAlindon, T.
    OSTEOPOROSIS INTERNATIONAL, 2019, 30 : S519 - S520
  • [28] RESULTS FROM A 52-WEEK, PHASE 2A STUDY OF AN INTRA- ARTICULAR, WNT PATHWAY INHIBITOR, SM04690, FOR KNEE OSTEOARTHRITIS
    Yazici, Y.
    Mcalindon, T.
    Gibofsky, A.
    Lane, N.
    Clauw, D.
    Swearingen, C.
    Difrancesco, A.
    Tambiah, J.
    Hochberg, M.
    OSTEOPOROSIS INTERNATIONAL, 2018, 29 : S51 - S52
  • [29] Assessment of Health-Related Quality of Life in a 52-Week, Phase 2, Randomized, Controlled Trial of a Novel, Intra-Articular, Wnt Pathway Inhibitor (SM04690) for Treatment of Knee Osteoarthritis
    Strand, Vibeke
    Ghandehari, Heli
    Swearingen, Christopher
    Tambiah, Jeyanesh
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [30] INTEGRATED SAFETY SUMMARY OF THE NOVEL, INTRA-ARTICULAR AGENT LORECIVIVINT (SM04690), A CLK/DYRK1A INHIBITOR THAT MODULATES THE WNT PATHWAY, IN SUBJECTS WITH KNEE OSTEOARTHRITIS
    Simsek, I.
    Swearingen, C.
    Kennedy, S.
    Tambiah, J.
    Damatarca, C.
    Yazici, Y.
    Lane, N.
    Hochberg, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 117 - 117
12345